Sequencing of hormonal therapy in breast cancer

James N. Ingle

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Hormonal therapy plays an integral role in the management of the majority of women with breast cancer who can be considered to have hormone-dependent breast cancer because of the presence of the molecular predictive markers, estrogen receptor and progesterone receptor. Numerous hormonal agents are available from multiple classes of drugs, including selective estrogen receptor modulators, aromatase inhibitors, progestins, androgens, and luteinizing hormone-releasing hormone analogues. Multiple clinical trials involving these agents have been conducted which permit an evidence-based approach to the development of a sequencing strategy for treatment of women with breast cancer.

Original languageEnglish (US)
Pages (from-to)332-337
Number of pages6
JournalBreast Journal
Volume8
Issue number6
DOIs
StatePublished - Nov 2002

Fingerprint

Breast Neoplasms
Play Therapy
Selective Estrogen Receptor Modulators
Aromatase Inhibitors
Progestins
Progesterone Receptors
Gonadotropin-Releasing Hormone
Estrogen Receptors
Androgens
Therapeutics
Clinical Trials
Hormones
Pharmaceutical Preparations

Keywords

  • Adjuvant
  • Breast cancer
  • Hormonal therapy
  • Metastatic
  • Sequencing

ASJC Scopus subject areas

  • Internal Medicine
  • Oncology

Cite this

Sequencing of hormonal therapy in breast cancer. / Ingle, James N.

In: Breast Journal, Vol. 8, No. 6, 11.2002, p. 332-337.

Research output: Contribution to journalArticle

Ingle, James N. / Sequencing of hormonal therapy in breast cancer. In: Breast Journal. 2002 ; Vol. 8, No. 6. pp. 332-337.
@article{904bff87934940308adc28b3a4bc6762,
title = "Sequencing of hormonal therapy in breast cancer",
abstract = "Hormonal therapy plays an integral role in the management of the majority of women with breast cancer who can be considered to have hormone-dependent breast cancer because of the presence of the molecular predictive markers, estrogen receptor and progesterone receptor. Numerous hormonal agents are available from multiple classes of drugs, including selective estrogen receptor modulators, aromatase inhibitors, progestins, androgens, and luteinizing hormone-releasing hormone analogues. Multiple clinical trials involving these agents have been conducted which permit an evidence-based approach to the development of a sequencing strategy for treatment of women with breast cancer.",
keywords = "Adjuvant, Breast cancer, Hormonal therapy, Metastatic, Sequencing",
author = "Ingle, {James N.}",
year = "2002",
month = "11",
doi = "10.1046/j.1524-4741.2002.08602.x",
language = "English (US)",
volume = "8",
pages = "332--337",
journal = "Breast Journal",
issn = "1075-122X",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Sequencing of hormonal therapy in breast cancer

AU - Ingle, James N.

PY - 2002/11

Y1 - 2002/11

N2 - Hormonal therapy plays an integral role in the management of the majority of women with breast cancer who can be considered to have hormone-dependent breast cancer because of the presence of the molecular predictive markers, estrogen receptor and progesterone receptor. Numerous hormonal agents are available from multiple classes of drugs, including selective estrogen receptor modulators, aromatase inhibitors, progestins, androgens, and luteinizing hormone-releasing hormone analogues. Multiple clinical trials involving these agents have been conducted which permit an evidence-based approach to the development of a sequencing strategy for treatment of women with breast cancer.

AB - Hormonal therapy plays an integral role in the management of the majority of women with breast cancer who can be considered to have hormone-dependent breast cancer because of the presence of the molecular predictive markers, estrogen receptor and progesterone receptor. Numerous hormonal agents are available from multiple classes of drugs, including selective estrogen receptor modulators, aromatase inhibitors, progestins, androgens, and luteinizing hormone-releasing hormone analogues. Multiple clinical trials involving these agents have been conducted which permit an evidence-based approach to the development of a sequencing strategy for treatment of women with breast cancer.

KW - Adjuvant

KW - Breast cancer

KW - Hormonal therapy

KW - Metastatic

KW - Sequencing

UR - http://www.scopus.com/inward/record.url?scp=0036848928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036848928&partnerID=8YFLogxK

U2 - 10.1046/j.1524-4741.2002.08602.x

DO - 10.1046/j.1524-4741.2002.08602.x

M3 - Article

C2 - 12390355

AN - SCOPUS:0036848928

VL - 8

SP - 332

EP - 337

JO - Breast Journal

JF - Breast Journal

SN - 1075-122X

IS - 6

ER -